GT200500130A - Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen - Google Patents

Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen

Info

Publication number
GT200500130A
GT200500130A GT200500130A GT200500130A GT200500130A GT 200500130 A GT200500130 A GT 200500130A GT 200500130 A GT200500130 A GT 200500130A GT 200500130 A GT200500130 A GT 200500130A GT 200500130 A GT200500130 A GT 200500130A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical compositions
compositions containing
crystal form
procedure
preparation
Prior art date
Application number
GT200500130A
Other languages
English (en)
Inventor
Stephane Horvath
Isabelle Demuynck
Gerard Damien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500130(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200500130A publication Critical patent/GT200500130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

LA PRESENTE INVENCION SE REFIERE A LA FORMA CRISTALINA ALFA DEL RANELATO DE ESTRONCIO, A SU PROCEDIMIENTO DE PREPARACION ASI COMO A LAS COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN.
GT200500130A 2004-09-30 2005-05-27 Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen GT200500130A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410335A FR2875807B1 (fr) 2004-09-30 2004-09-30 Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
GT200500130A true GT200500130A (es) 2005-12-20

Family

ID=34942420

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500130A GT200500130A (es) 2004-09-30 2005-05-27 Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen

Country Status (42)

Country Link
US (2) US7459568B2 (es)
EP (2) EP1642897B9 (es)
JP (2) JP2006104184A (es)
KR (1) KR100816590B1 (es)
CN (1) CN100391956C (es)
AP (1) AP1930A (es)
AR (1) AR049395A1 (es)
AT (1) ATE411308T1 (es)
AU (1) AU2005202718B2 (es)
BR (1) BRPI0502228A (es)
CA (1) CA2508824C (es)
CO (1) CO5710195A1 (es)
CR (1) CR7876A (es)
CY (1) CY1108797T1 (es)
DE (1) DE602005010359D1 (es)
DK (1) DK1642897T3 (es)
EA (1) EA008474B1 (es)
EC (1) ECSP055859A (es)
ES (1) ES2314593T3 (es)
FR (1) FR2875807B1 (es)
GE (1) GEP20074106B (es)
GT (1) GT200500130A (es)
HK (1) HK1086260A1 (es)
HR (1) HRP20080652T3 (es)
IL (1) IL169237A (es)
MA (1) MA27815A1 (es)
MX (1) MXPA05006407A (es)
NO (1) NO333948B1 (es)
NZ (1) NZ540802A (es)
OA (1) OA13013A (es)
PA (1) PA8638201A1 (es)
PE (1) PE20060364A1 (es)
PL (1) PL1642897T3 (es)
PT (1) PT1642897E (es)
RS (1) RS51110B (es)
SA (1) SA05260168B1 (es)
SG (1) SG121035A1 (es)
SI (1) SI1642897T1 (es)
TW (1) TWI367881B (es)
UA (1) UA80008C2 (es)
WO (1) WO2006035122A1 (es)
ZA (1) ZA200504937B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
CN101206208B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析雷尼酸锶原料及其制剂的方法
RU2011116926A (ru) 2008-09-29 2012-11-10 Рациофарм ГмбХ (DE) Безводная и гидратная формы ранелата стронция
IT1398542B1 (it) 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en) 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) * 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
ZA956029B (en) 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
AU2002341991A1 (en) * 2001-10-03 2003-04-14 Teva Pharmaceutical Industries Ltd. Methods for the purification of levofloxacin
EP2272501B1 (en) * 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
AU2003258109A1 (en) * 2002-08-06 2004-02-23 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr) 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
HK1086260A1 (en) 2006-09-15
TWI367881B (en) 2012-07-11
NZ540802A (en) 2006-11-30
MA27815A1 (fr) 2006-04-03
AR049395A1 (es) 2006-07-26
AP1930A (en) 2008-12-15
DE602005010359D1 (de) 2008-11-27
EA200500842A1 (ru) 2006-04-28
DK1642897T3 (da) 2009-01-26
PT1642897E (pt) 2008-11-27
US7459568B2 (en) 2008-12-02
NO20052998L (no) 2006-03-31
RS51110B (sr) 2010-10-31
JP2006104184A (ja) 2006-04-20
ES2314593T3 (es) 2009-03-16
WO2006035122A1 (fr) 2006-04-06
US7745482B2 (en) 2010-06-29
EP1642897A1 (fr) 2006-04-05
FR2875807A1 (fr) 2006-03-31
AU2005202718B2 (en) 2010-09-16
IL169237A (en) 2010-12-30
CA2508824A1 (fr) 2006-03-30
FR2875807B1 (fr) 2006-11-17
SA05260168B1 (ar) 2009-02-25
PA8638201A1 (es) 2006-05-16
BRPI0502228A (pt) 2006-05-09
US20080312314A1 (en) 2008-12-18
EA008474B1 (ru) 2007-06-29
US20060069271A1 (en) 2006-03-30
JP2010132669A (ja) 2010-06-17
MXPA05006407A (es) 2006-04-05
KR100816590B1 (ko) 2008-03-24
NO333948B1 (no) 2013-10-28
UA80008C2 (uk) 2007-08-10
EP1944302A1 (fr) 2008-07-16
OA13013A (fr) 2006-11-10
ZA200504937B (en) 2006-04-26
CN100391956C (zh) 2008-06-04
AU2005202718A1 (en) 2006-04-13
CY1108797T1 (el) 2014-04-09
CO5710195A1 (es) 2006-12-29
HRP20080652T3 (en) 2009-01-31
CA2508824C (fr) 2009-03-24
PL1642897T3 (pl) 2009-04-30
AP2005003323A0 (en) 2005-06-30
ECSP055859A (es) 2006-09-18
TW200610758A (en) 2006-04-01
NO20052998D0 (no) 2005-06-17
SG121035A1 (en) 2006-04-26
CN1754878A (zh) 2006-04-05
GEP20074106B (en) 2007-05-10
KR20060049966A (ko) 2006-05-19
PE20060364A1 (es) 2006-06-17
SI1642897T1 (sl) 2009-02-28
ATE411308T1 (de) 2008-10-15
EP1642897B1 (fr) 2008-10-15
CR7876A (es) 2007-12-10
EP1642897B9 (fr) 2009-08-12

Similar Documents

Publication Publication Date Title
GT200500130A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CR8246A (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
PA8671301A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización
NI200600240A (es) FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
UY33735A (es) Compuestos antivirales
HN2006018410A (es) Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
CR11861A (es) Compuestos organicos
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
CR10557A (es) Bencilaminas, un proceso para la produccion y su uso como agentes antiinflamatorios
HN2009000856A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen